Incorporating these tools in clinical practice has profoundly changed the decision-making for adjuvant chemotherapy for patients with ER+/HER2- early breast cancer and the results from large prospective adjuvant trials have strengthened the clinical utility of multigene assays in this setting. Here, ESR1 is linked to breast cancer.